Nanjing Immunophage Biotech Co., Ltd
Clinical trials sponsored by Nanjing Immunophage Biotech Co., Ltd, explained in plain language.
-
New oral cancer drug begins human testing
Disease control Recruiting nowThis early-stage study is testing a new oral medication called IPG1094 in patients with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine safe dosage levels and then expand to see if the drug shows anti-tumor activity agai…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill tested to fight serious kidney disease in lupus patients
Disease control Recruiting nowThis study is testing a new oral medication called IPG11406 for people with lupus nephritis, a serious kidney disease caused by lupus. The main goals are to find a safe dose and see if the drug shows early signs of helping control the disease by looking at kidney function and imm…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New pill targets tough cancers: first human trial begins
Disease control Recruiting nowThis early-stage trial is testing a new oral medication called IPG7236 in adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine safe dosage levels and then expand to specific cancer types including kidney, breast, …
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC